Citizens Maintains Market Outperform on Sagimet Biosciences, Raises Price Target to $29

Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying

Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to survive another

HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $29 price target.

Sagimet Biosciences’ AURORA Phase 3 Clinical Trial Of FASN Inhibitor Denifanstat In Moderate To Severe Acne Is On Track To Initiate Enrollment In Q4 2026

All clinical trial sites identified and CRO retainedPatient screening expected to begin in October 2026,with first patient to be enrolled shortly afterFOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet

Sagimet Biosciences shares are trading higher after Citizens raised its price target on the stock from $12 to $29.